1 Min Read
Jan 3 (Reuters) - Newron Pharmaceuticals Spa
* Newron announces encouraging preliminary results of its phase IIa study with Evenamide in patients with schizophrenia Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.